PURR
NASDAQ · Biotechnology

Hyperliquid Strategies

Mid-Cap Stocks Biotech Stocks Healthcare Stocks
$12.85
-1.24 (-8.80%)
As of Sep 27, 10:25 PM ET ·
Analyst Consensus
Strong Buy
9
Analysts
Moderate
Coverage
Buy 8 89%
Hold 1 11%
Sell 0 0%
Price Target
Analyst Price Target +31.9% upside
Low Target $12.34
Average Target $16.95
High Target $26.10
Current Price $12.85
Current
$12.85
Target
$16.95
$12.34 $16.95 avg $26.10
Scenario Analysis
Bear Case
$12.34
-4.0%
Low target
Base Case
$16.95
+31.9%
Avg target
Bull Case
$26.10
+103.1%
High target
Risk/Reward
26.0x
Highly favorable
Price in Context
52-Week High
$14.76
-12.9% from high
52-Week Low
$3.01
+326.9% from low
Target vs 52W High
$16.95
+14.8% vs high
Peer Consensus — Biotechnology
Stock Consensus Analysts Buy % Target Upside
ABBV
Abbvie Inc
 Strong Buy 39 82% $257.58 -3.3%
AMGN
Amgen Inc
 Hold 43 47% $190.87 -54.4%
GILD
Gilead Sciences Inc
 Strong Buy 37 81% $362.68 +138.3%
VRTX
Vertex Pharmaceuticals Inc
 Strong Buy 36 81% $438.34 -16.9%
REGN
Regeneron Pharmaceuticals
 Buy 38 68% $76.80 -89.8%
MRNA
Moderna Inc
 Hold 30 37% $149.45 -24.2%
NTRA
Natera Inc
 Strong Buy 30 87% $142.91 -65.3%
RVMD
Revolution Medicines Inc
 Strong Buy 28 93% $114.11 -43.4%